$ZLAB News

Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?

Zai Lab: Revenue Growth And Zoci's Upside Optionality

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

Zai Lab (ZLAB) Rebounds Following Earnings While Its Undervalued Narrative Faces A Fresh Test

Zai Lab Q2 Earnings Call Highlights

Citigroup Maintains Buy on Zai Lab, Raises Price Target to $45

Zai Lab Ltd (ZLAB) (Q2 2026) Earnings Call Highlights: Global Biopharma Inflection Point with U. ...

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

Zai Lab Q2 EPS $(0.46) Misses $(0.06) Estimate, Sales $105.751M Beat $105.323M Estimate

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

Zai Lab Says FDA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3 Antibody-Drug Conjugate, For Treatment Of Neuroendocrine Carcinomas

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy

Zai Lab Announces EMA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3-Targeting Antibody-Drug Conjugate, For Treatment Of Pulmonary Neuroendocrine Carcinomas

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer